Clinical trials: Ticagrelor
Peripheral Artery Disease, Type 2 Diabetes
Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes
The hypothesis being that both aspirin-ticagrelor and ticagrelor monotherapy will be superior to aspirin monotherapy in the reduction of whole blood viscosity at the end of each 4 week treatment period.
- Trial name
- NCT02325466
- Testing
- Aspirin, Ticagrelor
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Coronary Artery Disease
Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease
The recommended antiplatelet treatment regimen for patients affected by acute coronary syndromes (ACS) and those undergoing percutaneous coronary intervention (PCI) consists in the combination of aspirin and a P2Y12 receptor…
- Trial name
- SWAP-4 (NCT02287909)
- Testing
- Clopidogrel, Ticagrelor
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- University of Florida
Acute Coronary Syndrome, Angina, Unstable
Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel
Patients with troponin-negative acute coronary syndrome (ACS) are not routinely pre-treated with P2Y12 inhibitors and the rate of high on-treatment platelet reactivity (HPR) remains elevated after a loading dose of ticagrelor at…
- Trial name
- NCT02925923
- Testing
- Ticagrelor, Eptifibatide, Clopidogrel
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Alabama at Birmingham
Coronary Artery Disease
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study
Polymorphisms of the cytochrome P450 (CYP) 2C19 enzyme has been consistently shown to modulate clopidogrel response. Accordingly, the Food and Drug Administration (FDA) has issued a warning on the potential for reduced efficacy…
- Trial name
- NCT03489863
- Testing
- Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Florida
Chronic Kidney Diseases, Heart Attack
Chronic Kidney Disease (CKD) Platelet Study
This study evaluates how aspirin, clopidogrel and ticagrelor work in people with chronic kidney disease (CKD) compared to people with normal kidneys.
- Conditions
- Chronic Kidney Diseases, Heart Attack, Stroke, Ischemic
- Trial name
- NCT03649711
- Testing
- Ticagrelor 90mg, Clopidogrel 75mg, Aspirin 81 mg
- Where
- 2 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Acute Coronary Syndrome
Antithrombotic Effects of Ticagrelor Versus Clopidogrel
The purpose of this study is to determine whether treatment with ticagrelor (plus aspirin and bivalirudin) is more effective than treatment with clopidogrel (plus aspirin and bivalirudin).
- Trial name
- NCT01642238
- Testing
- Ticagrelor + ASA + Bivalirudin, Clopidogrel + ASA + Bivalirudin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Juan J Badimon
Coronary Artery Disease
The Platelet Aggregation After tiCagrelor Inhibition and FentanYl Trial (PACIFY)
With potent analgesic properties, perceived hemodynamic benefits and limited alternatives, opiates are the analgesic mainstay for acute coronary syndrome (ACS) patients reporting peri-procedural pain or nitrate-resistant chest…
- Trial name
- PACIFY (NCT02683707)
- Testing
- Removal of Fentanyl from peri-procedural analgesia, Fentanyl, Lidocaine
- Where
- United States
- Volunteers
- 212 people
- Sponsor
- Johns Hopkins University
Coronary Artery Disease
NIRS Ticagrelor Evaluation
The Impact of Ticagrelor on Coronary Atherosclerotic Lipid Pool and Inflammation Assessed by Near-Infrared Spectroscopy study will evaluate whether ticagrelor leads to a 20% reduction in the LCBI with NIRS/IVUS suggesting…
- Trial name
- NCT02282332
- Testing
- Ticagrelor
- Volunteers
- 30 people
- Sponsor
- Medstar Health Research Institute
Percutaneous Coronary Intervention
Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention
During a percutaneous coronary intervention (PCI), Fentanyl is commonly used for sedation. Ticagrelor is also routinely used as anti-platelet agent during PCI.
- Trial name
- FACTPCI (NCT03476369)
- Testing
- Fentanyl, Ticagrelor 90Mg Tablet
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- The Guthrie Clinic
Type-2 Diabetes Mellitus, Coronary Artery Disease
Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients
The purpose of this study is to determine whether treatment with ticagrelor + aspirin is more effective than treatment with clopidogrel + aspirin in patients with type-2 diabetes.
- Trial name
- NCT01823510
- Testing
- Ticagrelor + Aspirin, Clopidogrel + Aspirin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Juan J Badimon
Migraine, Headache
Ticagrelor Therapy for RefrACTORy Migraine Study
This is a prospective, open-label, single-arm pilot study treating 40 subjects to assess the hypothesis that P2Y, G protein-coupled 12 (P2Y12) inhibition with Brilinta/ticagrelor (90 mg by mouth (PO) twice a day) reduces episodic…
- Conditions
- Migraine, Headache, Migraine Headache
- Trial name
- TRACTOR (NCT02518464)
- Testing
- Ticagrelor 90 mg twice per day
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Columbia University
Coronary Artery Disease
In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients
Cangrelor is a potent intravenous P2Y12 receptor inhibitor with rapid onset and offset of action associated with a greater reduction in ischemic events, including stent thrombosis, in patients undergoing stent procedures who have…
- Trial name
- NCT02081443
- Testing
- Ticagrelor 180mg, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Florida
Myocardial Injury
Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery
The purpose of this pilot study is to establish the rate of cardiovascular events in patients with elevated troponins levels after major, non-cardiac surgery and to evaluate the efficacy and safety of FDA approved study drug…
- Trial name
- INTREPID (NCT02291419)
- Testing
- ticagrelor, aspirin
- Where
- 24 sites in United States
- Volunteers
- 6 people
- Sponsor
- The Cleveland Clinic
Stable Coronary Heart Disease (CHD)
Ticagrelor China Pharmacokinetic/Pharmacodynamic Study
open label, single centre, randomised, Phase IV, pharmacokinetic, pharmacodynamic, and safety study to evaluate single and multiple doses of 45, 60, and 90 mg of ticagrelor in Chinese patients with stable coronary heart disease
- Trial name
- NCT02064985
- Testing
- Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)
- Where
- China
- Volunteers
- 61 people
- Sponsor
- AstraZeneca
Atrial Fibrillation
Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
There are insufficient data on the safety and efficacy of edoxaban plus antiplatelet therapy in subjects with atrial fibrillation (AF) following percutaneous intervention (PCI) with stenting.
- Trial name
- ENTRUST-AF-PCI (NCT02866175)
- Testing
- Edoxaban, Clopidogrel, Prasugrel
- Where
- 200 sites in Austria, Belgium and 16 more
- Volunteers
- 1,506 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Acute Ischaemic Stroke, Transient Ischaemic Attack
THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events
- Trial name
- THALES (NCT03354429)
- Testing
- Ticagrelor
- Where
- 387 sites in Argentina, Australia and 26 more
- Volunteers
- 11,016 people
- Sponsor
- AstraZeneca
Sickle Cell Disease
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
The purpose of the study is to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease
- Trial name
- HESTIA3 (NCT03615924)
- Testing
- Ticagrelor
- Where
- 55 sites in United States, Belgium and 14 more
- Volunteers
- 193 people
- Sponsor
- AstraZeneca
Coronary Artery Disease, Acute Coronary Syndrome
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Recently, two new oral P2Y12 antagonists have been approved for clinical use: prasugrel, a third generation thienopyridine, and ticagrelor, a first in class cyclopentyltriazolopyrimidine (CPTP).
- Trial name
- SWAP3 (NCT02016170)
- Testing
- Ticagrelor 180mg, Prasugrel 10mg, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- University of Florida
Non-ST or ST Elevation Acute Coronary Syndromes
A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS
The purpose of this study is to test the hypothesis that the onset of the antiplatelet effect of ticagrelor is more rapid and greater than clopidogrel in Chinese patients with ACS.
- Trial name
- HouYi (NCT01864005)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Coronary Artery Disease, Peripheral Arterial Disease
Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies
Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations.
- Conditions
- Coronary Artery Disease, Peripheral Arterial Disease, Atrial Fibrillation
- Trial name
- NCT03718429
- Testing
- Rivaroxaban 2.5 mg Tablet
- Where
- 2 sites in United States
- Volunteers
- 86 people
- Sponsor
- University of Florida